BriaCell Therapeutics Corp.

BCTX | $2.19 -5.6% -5.94% 140K

(0.0% 1d) (23.2% 1m) (-61.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 34,999,980
https://www.briacell.com
Sec Filling | Patents | 2022 employees

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

cancer

add to watch list Paper trade email alert is off

Day One Biopharmaceuticals Inc

DAWN 4 | $14.98 -4.89% -5.14% 1.4M

Professional, Scientific, and T...

(0.0% 1d) (-0.4% 1m) (12.4% 1y) (0.0% 2d) (0.0% 3d) (5.5% 7d) (22.59% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,308,909,902
https://dayonebio.com
Sec Filling | Patents | 20 employees

(US) Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

treatment diagnostics cancer

add to watch list Paper trade email alert is off

Werewolf Therapeutics Inc

HOWL | $5.91 0.68% 0.68% 120K

Professional, Scientific, and T...

(0.0% 1d) (-3.9% 1m) (142.6% 1y) (0.0% 2d) (0.5% 3d) (6.9% 7d) (-70.97% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 256,182,915
https://werewolftx.com
Sec Filling | Patents | n/a employees

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

cancer immunotherapy msa treatment

add to watch list Paper trade email alert is off

Singular Genomics Systems Inc

OMIC | $0.3925 0.93% 0.92% 120K

Professional, Scientific, and T...

(0.0% 1d) (-23.6% 1m) (-61.9% 1y) (0.0% 2d) (0.0% 3d) (6.1% 7d) (-11.2% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 29,016,959
https://singulargenomics.com
Sec Filling | Patents | 138 employees

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

t-cell

add to watch list Paper trade email alert is off

Cyclo Therapeutics Inc - Class A

CYTH | $1.19 -0.83% -0.84% 57K

Professional, Scientific, and T...

(0.0% 1d) (-16.1% 1m) (69.2% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (-56.54% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 34,171,731
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

cholesterol genetic alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Reneo Pharmaceuticals Inc

RPHM | $1.74 -1.14% -1.15% 83K

Professional, Scientific, and T...

(0.0% 1d) (6.6% 1m) (-81.9% 1y) (0.0% 2d) (0.0% 3d) (6.6% 7d) (616.69% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 58,152,206
https://reneopharma.com
Sec Filling | Patents | 32 employees

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

energy renewable genetic metabolic

add to watch list Paper trade email alert is off

TransCode Therapeutics Inc

RNAZ | $0.49 -2.39% -2.45% 110K

Professional, Scientific, and T...

(0.0% 1d) (-28.6% 1m) (-92.9% 1y) (0.0% 2d) (0.0% 3d) (-6.8% 7d) (31.17% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 2,845,946
https://www.transcodetherapeutics.com
Sec Filling | Patents | 2021 employees

TransCode Therapeutics is an emerging RNA oncology company created to realize its belief that cancer can be defeated through the intelligent design of RNA therapeutics. This belief is based on a new approach to address what TransCode believes has been the most intractable challenge in RNA therapeutics: delivering an oligonucleotide to its target before the body’s immune system can attack and dismantle it. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. TransCode’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which TransCode believes has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. TransCode anticipates submitting an IND, in the second half of 2021 to support initiation of a Phase 0 clinical study with TTX-MC138.

cancer pancreatic glioblastoma

add to watch list Paper trade email alert is off

ImmunoPrecise Antibodies Ltd

IPA | $1.24 0.0% 150K

Professional, Scientific, and T...

(0.0% 1d) (-9.9% 1m) (-56.1% 1y) (0.0% 2d) (0.0% 3d) (2.4% 7d) (74.9% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 32,630,922
http://www.immunoprecise.com/
Sec Filling | Patents | 2021 employees

(CA) IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company's therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.

covid antibody

add to watch list Paper trade email alert is off